BIVI Biovie Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: BIVI

Price (delayed)

$0.4904

Market cap

$19.55M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.17

Enterprise value

$9.59M

BioVie Inc. is developing BIV201 (continuous infusion terlipressin) an Orphan Drug candidate for the treatment of ascites due to advanced liver cirrhosis. First-to-market Orphan therapies typically receive 7 years of ...

Highlights
BIVI's debt is down by 23% YoY and by 17% QoQ
The EPS has grown by 21% YoY and by 19% from the previous quarter
The net income is up by 14% since the previous quarter but it is down by 4.9% year-on-year
BIVI's quick ratio has plunged by 75% YoY and by 10% from the previous quarter
BIVI's equity has dropped by 71% year-on-year
Sector: Healthcare
Industry: Biotechnology
Website: http://www.biovieinc.com
Peers: NWBO

Key stats

What are the main financial stats of BIVI
Market
Shares outstanding
39.87M
Market cap
$19.55M
Enterprise value
$9.59M
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
2.47
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$39.25M
EBITDA
-$39.04M
Free cash flow
-$41.11M
Per share
EPS
-$1.17
Free cash flow per share
-$1.08
Book value per share
$0.2
Revenue per share
$0
TBVPS
$0.54
Balance sheet
Total assets
$21.49M
Total liabilities
$14M
Debt
$10.26M
Equity
$7.49M
Working capital
$6.58M
Liquidity
Debt to equity
1.37
Current ratio
1.47
Quick ratio
1.45
Net debt/EBITDA
0.26
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-137.9%
Return on equity
-332.2%
Return on invested capital
-688.3%
Return on capital employed
-522.7%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BIVI stock price

How has the Biovie stock price performed over time
Intraday
-1.92%
1 week
2.17%
1 month
-1.27%
1 year
-93.25%
YTD
-61.08%
QTD
-7.23%

Financial performance

How have Biovie's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$44.41M
Net income
-$43.27M
Gross margin
N/A
Net margin
N/A
The company's operating income fell by 26% YoY but it rose by 6% QoQ
The net income is up by 14% since the previous quarter but it is down by 4.9% year-on-year

Growth

What is Biovie's growth rate over time

Valuation

What is Biovie stock price valuation
P/E
N/A
P/B
2.47
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS has grown by 21% YoY and by 19% from the previous quarter
The price to book (P/B) is 79% lower than the last 4 quarters average of 11.5
BIVI's equity has dropped by 71% year-on-year

Efficiency

How efficient is Biovie business performance
Biovie's ROIC has decreased by 45% YoY and by 19% from the previous quarter
BIVI's ROE is down by 16% QoQ but it is up by 8% YoY
The company's return on assets fell by 3.1% QoQ but it rose by 2.7% YoY

Dividends

What is BIVI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BIVI.

Financial health

How did Biovie financials performed over time
Biovie's total assets is 54% more than its total liabilities
Biovie's current ratio has shrunk by 75% YoY and by 15% QoQ
BIVI's quick ratio has plunged by 75% YoY and by 10% from the previous quarter
BIVI's debt is 37% higher than its equity
BIVI's debt to equity has soared by 169% YoY but it is down by 16% from the previous quarter
BIVI's equity has dropped by 71% year-on-year

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.